An interventional study of Lens 1 ( stenfilcon A ) and Lens 2 ( comfilcon A ) in Astigmatism and Ametropia, sponsored by CooperVision International Limited (CVIL). Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-23.
Sponsored by CooperVision International Limited (CVIL) (part of CooperCompanies) · Not applicable, Interventional, and Treatment
Among 34 studies in Astigmatism by CooperVision International Limited (CVIL) — 3 open to participants now, 3 under way, none of them phase 3. Astigmatism · CooperVision International Limited (CVIL).
Among the 34 studies in Astigmatism by CooperVision International Limited (CVIL), this one is the 27th largest by enrollment of the 33 interventional ones, is one of 4 that started in 2026, is one of 33 with no phase, and was the 31st registered.
417 studies on the registry are indexed under Astigmatism; 50 are open to participants now.
This study's enrollment of 29 is below the median of 55 across 325 interventional studies indexed under Astigmatism.
Browse Astigmatism studies →3 of the 34 studies in Astigmatism by CooperVision International Limited (CVIL) are open now, in 2 countries. Each count lists the studies.
Of the 32 Astigmatism studies recruiting now, 12 (38%) set no upper age limit and 15 (47%) stop at 75 or younger; 5 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →34 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 4 started in 2026.
Median enrollment 42 across the 33 interventional studies, 102 across the 1 observational. Of the 31 that completed or were terminated, 28 (90%) have results posted.
CooperVision International Limited (CVIL) is the lead sponsor of 138 studies on the registry; 6 are open to participants now.
Of its 74 completed or terminated interventional studies of FDA-regulated products, 66 (89%) have results posted.
3 of the studies in Astigmatism by CooperVision International Limited (CVIL) that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07751172CooperVision International Limited (CVIL)Evaluation of Orthokeratology Lenses With a 5MM Optic Zone Diameter | 2026-12 |
| NCT07898995CooperVision International Limited (CVIL)Clinical Performance and Outcomes After Toric Lens Transition | 2027-02 |
| NCT07829419CooperVision International Limited (CVIL)Evaluation of Two Monthly Silicone Hydrogel Multifocal Toric in Soft Contact Lens Wearers | 2027-09 |
Among the 34 studies in Astigmatism by CooperVision International Limited (CVIL), from their registry updates:
The aim of this study is to evaluate the agreement between subjective and objective toric lens prescriptions.
To evaluate agreement between subjective and objective optimized toric contact lens prescriptions.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All participants will be randomized to wear lens A
Device: Lens 1 ( stenfilcon A )
All participants will be randomized to wear lens B
Device: Lens 2 ( comfilcon A )
15 minutes of daily wear
15 minutes of daily wear
Subjective assessment of optimization of Toric lenses
Proportion of eyes in which the optimized toric lens cylinder axis determined by the subjective method agrees with that determined by the objective method within ±10 degrees (measured at a single time point).
Time frame: At the End of Baseline 15 minutes of daily wear
Plan to share: No
No publications or documents are linked to this record.
Ran from May 2026 to primary completion in Jul 2026, 1 month.
Of 106 industry-sponsored interventional studies with no phase under Astigmatism, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 19. This study's 1 month is below that.
Counting every sponsor, half of 183 studies reached it within 12 months; a quarter within 4 and three quarters within 26.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 23, 2026: primary completion Aug 2026 → Jul 2026 and completion Aug 2026 → Jul 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
CooperVision International Limited (CVIL) →